Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Sep;8(9):509-21.
doi: 10.1038/nrrheum.2012.97. Epub 2012 Jul 24.

Clinical features of polymyalgia rheumatica and giant cell arteritis

Affiliations
Review

Clinical features of polymyalgia rheumatica and giant cell arteritis

Carlo Salvarani et al. Nat Rev Rheumatol. 2012 Sep.

Abstract

Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are inflammatory diseases that typically affect white individuals >50 years. Women are affected ∼2-3 times more often than men. PMR and GCA occur together more frequently than expected by chance. The main symptoms of PMR are pain and stiffness in the shoulders, and often in the neck and pelvic girdle. Imaging studies reveal inflammation of joints and bursae of the affected areas. GCA is a large-vessel and medium-vessel arteritis predominantly involving the branches of the aortic arch. The typical clinical manifestations of GCA are new headache, jaw claudication and visual loss. PMR and GCA usually remit within 6 months to 2 years from disease onset. Some patients, however, have a relapsing course and might require long-standing treatment. Diagnosis of PMR and GCA is based on clinical features and elevated levels of inflammatory markers. Temporal artery biopsy remains the gold standard to support the diagnosis of GCA; imaging studies are useful to delineate large-vessel involvement in GCA. Glucocorticoids remain the cornerstone of treatment of both PMR and GCA, but patients with GCA require higher doses. Synthetic immunosuppressive drugs also have a role in disease management, whereas the role of biologic agents is currently unclear.

PubMed Disclaimer

References

    1. Arthritis Rheum. 1999 Feb;42(2):311-7 - PubMed
    1. Curr Opin Rheumatol. 2008 Jan;20(1):17-22 - PubMed
    1. Clin Exp Rheumatol. 2001 Sep-Oct;19(5):495-501 - PubMed
    1. Arthritis Rheum. 2001 Dec;44(12):2933-5 - PubMed
    1. Am J Pathol. 1999 Sep;155(3):765-74 - PubMed